Bispecific monoclonal antibody

Genmab and BioNTech Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates

Retrieved on: 
Friday, August 5, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Antibody, U.S. Securities and Exchange Commission, Risk, Pierre Geneves, BioNTech, Technology, Private Securities Litigation Reform Act, SEC, Cancer, Regeneron Pharmaceuticals, Infection, CD27, BNTX, Research, Environment, Annual report, NSCLC, Hoffmann-La Roche, Patient, Review, Risk management, Company, Large-cell lung carcinoma, Program, Biotechnology, Safety, Bispecific monoclonal antibody, Nature, Media release, Immunotherapy, Nasdaq, Cell membrane, RNA transfection, Pharmaceutical industry, Vaccine, Genentech, Pfizer, Genmab

Genmab A/S (Nasdaq: GMAB) and BioNTech SE (Nasdaq: BNTX, BioNTech) today announced an expansion of their global strategic collaboration to develop and commercialize novel immunotherapies for the treatment of cancer patients.

Key Points: 
  • Genmab A/S (Nasdaq: GMAB) and BioNTech SE (Nasdaq: BNTX, BioNTech) today announced an expansion of their global strategic collaboration to develop and commercialize novel immunotherapies for the treatment of cancer patients.
  • Under the expansion, Genmab and BioNTech will jointly work to research, develop, and commercialize novel monospecific antibody candidates for various cancer indications.
  • Under the expanded collaboration, the companies will jointly develop and commercialize, subject to regulatory approval, monospecific antibodies leveraging Genmabs proprietary HexaBody technology platform.
  • To develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies.

Zymeworks Announces Oral Presentation of Data from Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers at European Society for Medical Oncology (ESMO) Congress 2022 in Paris

Retrieved on: 
Monday, July 25, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Inc., U.S. Securities and Exchange Commission, Twitter, ADC, CEO, NYSE, HER2, Research, Bispecific monoclonal antibody, Forward-looking statement, Paris Expo Porte de Versailles, Private Securities Litigation Reform Act, COVID-19, Safety, Conjugation, European Society for Medical Oncology, Drug development, Security (finance), Patient, Memorial Sloan Kettering Cancer Center, ESMO, Engineering, CEST, Oncology, Chair, Pharmaceutical industry, Zymeworks

This presentation represents an important milestone for Zymeworks as the first opportunity to share clinical data from our zanidatamab zovodotin development program, said Kenneth Galbraith, Chair and CEO of Zymeworks.

Key Points: 
  • This presentation represents an important milestone for Zymeworks as the first opportunity to share clinical data from our zanidatamab zovodotin development program, said Kenneth Galbraith, Chair and CEO of Zymeworks.
  • Zymeworks will host a conference call to further discuss the clinical data presented at ESMO and provide an overview on future clinical development plans for zanidatamab zovodotin after the presentation.
  • Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics.
  • Zymeworks suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates.

Compugen to Release Second Quarter Results on Thursday, August 4, 2022

Retrieved on: 
Thursday, July 21, 2022
Science and technology in Asia, Bispecific monoclonal antibody, TIGIT, Research, Telephone, TEL, Immunotherapy, Company, Nasdaq, Compugen, AstraZeneca, Pharmaceutical industry, Bayer

HOLON, Israel, July 21, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that the Company will release its second quarter financial results on Thursday, August 4, 2022, before the U.S. financial markets open.

Key Points: 
  • HOLON, Israel, July 21, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that the Company will release its second quarter financial results on Thursday, August 4, 2022, before the U.S. financial markets open.
  • Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET.
  • To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S.,or +972-3-918-0644 internationally.
  • The call will be available via live webcast through Compugen's website, located at the following link .

Immunocore announces dosing of first patient with ImmTAV® bispecific for HIV

Retrieved on: 
Monday, July 11, 2022
Bill & Melinda Gates Foundation, Safety, HIV, Survival, Lists of countries and territories, Omicron, Melinda Gates, Infection, ImmTAC, COVID-19, ART, Adult, Gag, Private Securities Litigation Reform Act, Mum, Risk, U.S. Securities and Exchange Commission, Disease, Doctor of Philosophy, Imperial College London, Company, Hepatitis B virus, Cell, Pharmacokinetics, Nasdaq, Cancer, Autoimmunity, Autoimmune disease, TCR, HBV, HIV/AIDS, Patient, Immune system, Public health, HLA, Bispecific monoclonal antibody, Security (finance), Annual report, Pharmaceutical industry, Vaccine, Immunocore

IMC-M113V is the second candidate in development using Immunocores immunemobilising monoclonal T cell receptors against virus (ImmTAV) platform to enter clinical trials.

Key Points: 
  • IMC-M113V is the second candidate in development using Immunocores immunemobilising monoclonal T cell receptors against virus (ImmTAV) platform to enter clinical trials.
  • IMC-M113V targets a peptide derived from the Gag protein that is presented by HLA*A02 on the surface of HIV infected cells.
  • There are currently over 30 antiretroviral medications spanning six drug classes approved for the treatment of HIV.
  • HIV remains a major global public health challenge with the need for a functional cure said Lucy Dorrell MD, Head of Infectious Diseases at Immunocore.

The Jefferson Institute of Bioprocessing to Bring Biologics Training to Budd Bioworks

Retrieved on: 
Monday, June 27, 2022
Professional Services, Education, Health, Finance, University, Training, Biotechnology, Bispecific monoclonal antibody, Thomas Jefferson University, Science, LinkedIn, 2019 NCAA Division I baseball season, Protein, Research, TSX, Architecture, CIGI, Student, Workforce, CGT, Growth, Ownership, Commerce, Ecosystem, Industry, Textile, Partnership, Principal, Quality control, Budd Company, Health, Medicine, NASDAQ, Leadership, JIB, Twitter, Collier, Conference, Knowledge, Multimedia, Management, Financial services, Engineering

(Photo: Business Wire)

Key Points: 
  • (Photo: Business Wire)
    JIBs training services will enable life-changing therapies developed in Philadelphias Cellicon Valley to be supported by a well-trained bioprocessing workforce.
  • JIB will provide training services remotely and in the Budd Innovation Center located at 2450 W. Hunting Park Avenue.
  • We are excited about working with the Bioprocessing Training Center at Budd Bioworks, said Dr. Parviz Shamlou, Vice President at Thomas Jefferson University and Executive Director of the Jefferson Institute for Bioprocessing.
  • With this new relationship, JIB will be expanding upon the success of its core bioprocessing training facility and bringing its proven training programs to more audiences.

Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™

Retrieved on: 
Saturday, June 25, 2022
Cell, Autoimmunity, Bispecific monoclonal antibody, Annual report, Patient, ALT, Adult, HBV, Marketing, COVID-19, EASL, Cancer, Company, Research and development, Omicron, TCR, U.S. Securities and Exchange Commission, HBsAg, Cytokine, ImmTAC, Hepatitis, Hepatocyte, Pharmacokinetics, Infection, Immune system, HIV, ART, Risk, Alanine transaminase, Serum, Clinical trial, Private Securities Litigation Reform Act, Mum, Survival, DNA, Nasdaq, Autoimmune disease, Kinetics, Safety, Non-cirrhotic portal fibrosis, Security (finance), Pharmaceutical industry, Vaccine, Immunocore, IMC

IMC-I109V is a TCR bispecific designed to specifically eliminate HBV-infected hepatocytes expressing hepatitis B surface antigen (HBsAg) via T cell redirection.

Key Points: 
  • IMC-I109V is a TCR bispecific designed to specifically eliminate HBV-infected hepatocytes expressing hepatitis B surface antigen (HBsAg) via T cell redirection.
  • Since the mechanism results in hepatocyte lysis, transient liver enzyme increases are expected, necessitating a conservative dosing schedule in the Companys first-in-human study of IMC-I109V.
  • In this first cohort, three patients each received a single dose of 0.8 mcg, based on the minimum anticipated biological effect level (MABEL).
  • The dose in this initial cohort was well tolerated and was not associated with adverse events were reported in any patient.

Canadian High-tech Advanced Electrophoresis Solutions Ltd. Secured GCI-led Investment to Expand its Business in Biopharma Industry

Retrieved on: 
Tuesday, June 21, 2022
QA/QC, Doctor of Philosophy, ADC, FDA, Vaccine, Thermo Fisher Scientific, USC Michelson Center for Convergent Bioscience, Workflow, AES, Mab, Solution, University, Mass spectrometry, Partnership, Multimedia, Bispecific monoclonal antibody, QA, Fine chemical

CAMBRIDGE, ON, June 20, 2022 /PRNewswire/ - Cambridge-based life science high-tech Advanced Electrophoresis Solutions Ltd. (AES) has secured pre-A investment which was closed in April, to address the critical QA/QC bottlenecks in Biopharma.

Key Points: 
  • CAMBRIDGE, ON, June 20, 2022 /PRNewswire/ - Cambridge-based life science high-tech Advanced Electrophoresis Solutions Ltd. (AES) has secured pre-A investment which was closed in April, to address the critical QA/QC bottlenecks in Biopharma.
  • This round was AES's first institutional raise and was led by Toronto-based GCI Capital and Celtic House Asia Partners.
  • GCI Capital provided strategic advice through its subsidiary G-Force Innovation Hub to help AES accelerate its sales in the global market.
  • Founded in 2010 by Dr. Tiemin Huang, Advanced Electrophoresis Solutions Ltd. become a total solution provider of iCIEF technology serving the biopharma and protein chemistry industries.

Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies

Retrieved on: 
Thursday, June 16, 2022
Biotechnology, Health, Oncology, Antibody, Lymphatic system, ADC, Cancer, Intellectual property, Uncertainty, Security (finance), Therapy, COVID-19, Bioinvent, S&P, Genetics, Midcap, Technology, Person, Compliance, CEO, Company, Humanitarian use licenses, U.S. Securities and Exchange Commission, Daiichi Sankyo, Forward-looking statement, Research, Engineering, Nasdaq Stockholm, Risk, Drug discovery, EXEL, Esaxerenone, Genentech, Program, Acquisition, IO, Nasdaq, SEC, Twitter, Patient, Standard, Multimedia, Bispecific monoclonal antibody, EU, Vaccine, Pharmaceutical industry, Risk management, Kerosene, Exelixis, Limited, Facebook

BioInvent will be responsible for initial target and antibody discovery activities, and characterization of antibody mechanism of action.

Key Points: 
  • BioInvent will be responsible for initial target and antibody discovery activities, and characterization of antibody mechanism of action.
  • Exelixis will have the right to exercise an option to in-license any of the target programs upon identification of a development candidate directed to that target.
  • Upon option exercise, Exelixis will pay BioInvent an option exercise fee and will assume responsibility for all future development and commercialization activities for the development candidate, including potential ADC and bispecific antibody engineering activities.
  • Exelixis, the Exelixis logo, CABOMETYX and COMETRIQ are registered U.S. trademarks of Exelixis.

Medison Pharma Announces the Approvals by Health Canada and Therapeutics Goods Administration of KIMMTRAK® (tebentafusp) for the Treatment of Unresectable or Metastatic Uveal Melanoma

Retrieved on: 
Wednesday, June 8, 2022
Orbis, United Kingdom, TCR, Itch, Eye, Infection, Adult, Fever, Time, Headache, Vital signs, Socialist Union of Central-Eastern Europe, Nausea, Anti-CD3 monoclonal antibody, Survival, Fatigue, Ipilimumab, Melanoma, TGA, Minister of Health (Canada), CEO, Partnership, Mum, Hope, Hypotension, Uvea, Therapeutic Goods Administration, Princess Margaret Cancer Centre, Hypoxia, Pembrolizumab, Dacarbazine, Health Canada, Patient, Cancer, Uveal melanoma, Melanocyte, Pascal (microarchitecture), Cytokine release syndrome, Autoimmune disease, Diagnosis, Vomiting, Clinical trial, CRS, Population, Hazard ratio, Chills, ImmTAC, Rash, Bispecific monoclonal antibody, Regulatory affairs, Pharmaceutical industry, Vaccine, Medical device, Immunocore, EU, Medison

PETACH TIKVAH, Israel, June 8, 2022 /PRNewswire/ -- Today, Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, is pleased to announce the approval of KIMMTRAK® (tebentafusp) by Health Canada and Therapeutics Goods Administration (TGA) for the treatment of unresectable or metastatic uveal melanoma (mUM), a rare and aggressive form of melanoma that affects the eye.

Key Points: 
  • "The approvals of KIMMTRAK by Health Canada and TGA are a milestone for uveal melanoma patients in Canada and Australia," said Victor PapamoniodisVP International Markets at Medison.
  • "The approval of KIMMTRAK by Health Canada and TGA represent another positive step forward for uveal melanoma patients.
  • "For years, metastatic uveal melanoma patients have had to make do with therapeutic options not ideally suited for their condition," said.
  • Unresectable or metastatic uveal melanoma typically has a poor prognosis and had no approved treatment until KIMMTRAK.

Medison Pharma Announces the Approvals by Health Canada and Therapeutics Goods Administration of KIMMTRAK® (tebentafusp) for the Treatment of Unresectable or Metastatic Uveal Melanoma

Retrieved on: 
Wednesday, June 8, 2022
Orbis, United Kingdom, TCR, Itch, Eye, Infection, Adult, Fever, Time, Headache, Vital signs, Socialist Union of Central-Eastern Europe, Nausea, Anti-CD3 monoclonal antibody, Survival, Fatigue, Ipilimumab, Melanoma, TGA, Minister of Health (Canada), CEO, Partnership, Mum, Hope, Hypotension, Uvea, Therapeutic Goods Administration, Princess Margaret Cancer Centre, Hypoxia, Pembrolizumab, Dacarbazine, Health Canada, Patient, Cancer, Uveal melanoma, Melanocyte, Pascal (microarchitecture), Cytokine release syndrome, Autoimmune disease, Diagnosis, Vomiting, Clinical trial, CRS, Population, Hazard ratio, Chills, ImmTAC, Rash, Bispecific monoclonal antibody, Regulatory affairs, Pharmaceutical industry, Vaccine, Medical device, Immunocore, EU, Medison

PETACH TIKVAH, Israel, June 8, 2022 /PRNewswire/ -- Today, Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, is pleased to announce the approval of KIMMTRAK® (tebentafusp) by Health Canada and Therapeutics Goods Administration (TGA) for the treatment of unresectable or metastatic uveal melanoma (mUM), a rare and aggressive form of melanoma that affects the eye.

Key Points: 
  • "The approvals of KIMMTRAK by Health Canada and TGA are a milestone for uveal melanoma patients in Canada and Australia," said Victor PapamoniodisVP International Markets at Medison.
  • "The approval of KIMMTRAK by Health Canada and TGA represent another positive step forward for uveal melanoma patients.
  • "For years, metastatic uveal melanoma patients have had to make do with therapeutic options not ideally suited for their condition," said.
  • Unresectable or metastatic uveal melanoma typically has a poor prognosis and had no approved treatment until KIMMTRAK.